[
  {
    "ts": "2026-02-26T04:31:13+00:00",
    "headline": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
    "summary": "The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor",
    "url": "https://finance.yahoo.com/news/novo-nordisks-china-obesity-drug-043113091.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "6ca5da1b-6722-38a7-b2d7-398a6dedd5eb",
      "content": {
        "id": "6ca5da1b-6722-38a7-b2d7-398a6dedd5eb",
        "contentType": "STORY",
        "title": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
        "description": "",
        "summary": "The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor",
        "pubDate": "2026-02-26T04:31:13Z",
        "displayTime": "2026-02-26T04:31:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/2f4929ece0513781c2c8031526bc3e6e",
          "originalWidth": 1024,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/09hQCmD_hzreogiVWsq_UQ--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/2f4929ece0513781c2c8031526bc3e6e.cf.webp",
              "width": 1024,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VTi3w2RwIkJk2IUDUdfoJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2f4929ece0513781c2c8031526bc3e6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-china-obesity-drug-043113091.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-china-obesity-drug-043113091.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "3933.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T11:30:00+00:00",
    "headline": "Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforgl",
    "url": "https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-113000896.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "76f569b9-3207-3131-80ea-56f6e1233ab5",
      "content": {
        "id": "76f569b9-3207-3131-80ea-56f6e1233ab5",
        "contentType": "STORY",
        "title": "Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforgl",
        "pubDate": "2026-02-26T11:30:00Z",
        "displayTime": "2026-02-26T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-113000896.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-113000896.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]